Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence.
Raja
Shahzad G
SG
Department of Cardiac Surgery, Royal Hospital for Sick Children, Glasgow, United Kingdom. drrajashahzad@hotmail.com <drrajashahzad@hotmail.com>
Danton
Mark D
MD
MacArthur
Kenneth J
KJ
Pollock
James C
JC
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000818:Animals; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology*; D010879:Piperazines / Q000627:therapeutic use*; D011669:Pulmonary Wedge Pressure / Q000187:drug effects / Q000502:physiology*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases